181 related articles for article (PubMed ID: 29311468)
1. [Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis].
Shida T; Endo Y; Shiraishi T; Yoshioka T; Suzuki K; Kobayashi Y; Ono Y; Ito T; Inoue T
Yakugaku Zasshi; 2018; 138(1):83-90. PubMed ID: 29311468
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Rivera F; Valladares M; Gea S; López-Martínez N
J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of FOLFIRI-Based First-Line Regimens for Metastatic Colorectal Cancer Using Clinical Decision Analysis.
Shida T; Ono Y; Kobayashi Y; Ogura J; Hatakeyama S; Arakawa I; Inoue T; Yamaguchi H
Gan To Kagaku Ryoho; 2024 May; 51(5):541-547. PubMed ID: 38881065
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness Analysis of Panitumumab Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 for First-line Treatment of Patients with Wild-type RAS Metastatic Colorectal Cancer--Czech Republic Model Adaptation].
Fínek J; Skoupá J; Jandová P
Klin Onkol; 2015; 28(4):265-72. PubMed ID: 26299740
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
[TBL] [Abstract][Full Text] [Related]
8. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study.
Wen F; Yang Y; Zhang P; Zhang J; Zhou J; Tang R; Chen H; Zheng H; Fu P; Li Q
Cancer Biol Ther; 2015; 16(11):1577-84. PubMed ID: 26418570
[TBL] [Abstract][Full Text] [Related]
11. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M
Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
[TBL] [Abstract][Full Text] [Related]
14. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
Nagata N; Mishima H; Kurosawa S; Oba K; Sakamoto J
Clin Colorectal Cancer; 2017 Jun; 16(2):154-157.e1. PubMed ID: 28284575
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
Goldstein DA; Zeichner SB; Bartnik CM; Neustadter E; Flowers CR
Clin Colorectal Cancer; 2016 Mar; 15(1):1-6. PubMed ID: 26541320
[TBL] [Abstract][Full Text] [Related]
16. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
[TBL] [Abstract][Full Text] [Related]
17. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
[TBL] [Abstract][Full Text] [Related]
18. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Chu JN; Choi J; Ostvar S; Torchia JA; Reynolds KL; Tramontano A; Gainor JF; Chung DC; Clark JW; Hur C
Cancer; 2019 Jan; 125(2):278-289. PubMed ID: 30343509
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
